Document is current
Any future updates will be listed below
-
Authors
Dubois, Frank P. B. http://orcid.org/0000-0002-7654-6208
Shapira, Ofer
Greenwald, Noah F. http://orcid.org/0000-0002-7836-4379
Zack, Travis
Wala, Jeremiah
Tsai, Jessica W. http://orcid.org/0000-0003-0540-4330
Crane, Alexander
Baguette, Audrey http://orcid.org/0000-0001-8011-2341
Hadjadj, Djihad
Harutyunyan, Ashot S. http://orcid.org/0000-0002-9050-9315
Kumar, Kiran H.
Blattner-Johnson, Mirjam
Vogelzang, Jayne
Sousa, Cecilia
Kang, Kyung Shin
Sinai, Claire
Wang, Dayle K. http://orcid.org/0000-0002-2185-1782
Khadka, Prasidda
Lewis, Kathleen
Nguyen, Lan
Malkin, Hayley
Ho, Patricia http://orcid.org/0000-0002-4622-8188
O’Rourke, Ryan
Zhang, Shu
Gold, Rose
Deng, Davy
Serrano, Jonathan
Snuderl, Matija
Jones, Chris
Wright, Karen D.
Chi, Susan N.
Grill, Jacques
Kleinman, Claudia L. http://orcid.org/0000-0002-5158-7126
Goumnerova, Liliana C. http://orcid.org/0000-0002-2662-719X
Jabado, Nada http://orcid.org/0000-0003-2485-3692
Jones, David T. W. http://orcid.org/0000-0002-2036-5141
Kieran, Mark W.
Ligon, Keith L. http://orcid.org/0000-0002-7733-600X
Beroukhim, Rameen http://orcid.org/0000-0001-6303-3609
Bandopadhayay, Pratiti http://orcid.org/0000-0002-4175-4760
- License Information
-
More Information
Article History
Received: 30 October 2021
Accepted: 23 May 2022
First Online: 4 July 2022
Competing interests
: R.B. and P.B. receive grant funding from the Novartis Institute of Biomedical Research for an unrelated project, R.B. receives grant funding from Merck and P.B. has received grant funding from Deerfield Therapeutics for an unrelated project. P.B consults for QED Therapeutics, R.B. consults for and owns equity in Scorpion Therapeutics, and reports consulting or advisory roles for Novartis, Merck (I), Gilead Sciences (I) and ViiV Healthcare (I); research funding from Novartis; patents, royalties other intellectual property—Prognostic Marker for Endometrial Carcinoma (US patent application 13/911456, filed June 6, 2013), SF3B1 Suppression as a Therapy for Tumors Harboring SF3B1 Copy Loss (international application No. WO/2017/177191, PCT/US2017/026693, filed July 4, 2017), Compositions and Methods for Screening Pediatric Gliomas and Methods of Treatment Thereof (international application No. WO/2017/132574, PCT/US2017/015448, filed 1/27/2017). K.L.L. reports grants and personal fees from BMS, grants from Amgen, personal fees and other from Travera LLC, personal fees from Rarecyte, grants from Tragara, grants from Lilly, grants from Deciphera, grants from X4, grants from Charles River Labs and grants from Specicare, outside the submitted work; and has a patent US20160032359A1 pending. M.W.K. is now an employee of Day One Biopharmaceuticals. L.C.G. is the Co-Founder of Thromboprotea Inc. All the remaining authors declare no competing interests.
